Clinical trial

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

NCT00642018

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-03-01

PhasePHASE2

Study timeline

Study start (unknown)2008-03-01Date precision: month

Registry last updated2019-04-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

docetaxelDRUG · verified · RxNorm: docetaxel

LY2181308 sodiumDRUG

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Mapped research locations

MadridSpain1 BarcelonaSpain1 WarsawPoland1 MemphisTennessee, United States1 GdanskPoland1 HanoverGermany1 HeidelbergGermany1 FrankfurtGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00642018 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.